New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Ibrance (palbociclib) - Drug Insight and Market Forecast - 2030 ...

First-of-its-kind comparative analysis of real-world data in the CDK 4/6 inhibitor class supports benefits of IBRANCE combination therapy initially shown in clinical trials Among the data, Pfizer will ...

NEW YORK--(BUSINESS WIRE)-- As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE Ibrance (palbociclib) regimen for ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced updated progression-free survival (PFS) results from the Phase 3 PALOMA-2 trial reinforcing the clinical benefit of IBRANCE ® ...

Dublin, Feb. 14, 2023 (GLOBE NEWSWIRE) -- The "IBRANCE Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. "IBRANCE Drug Insight and Market ...

The FDA has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), endocrine therapy, and optionally ...

IBRANCE® (palbociclib) to be funded from 1 April for HR positive/HER2 negative (HR+/HER2–) advanced or metastatic breast cancer Pfizer New Zealand today welcomed the decision by PHARMAC to fund ...

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE ® (palbociclib) 125mg capsules, Pfizer’s metastatic ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in ...

Pfizer New Zealand today welcomed the provisional decision by PHARMAC to fund IBRANCE (palbociclib) for women with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative ...